Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 400 IDR 5.26%
Market Cap: 65.6T IDR
Have any thoughts about
Kalbe Farma Tbk PT?
Write Note

Kalbe Farma Tbk PT
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kalbe Farma Tbk PT
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Kalbe Farma Tbk PT
IDX:KLBF
Accrued Liabilities
Rp782.7B
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
8%
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Accrued Liabilities
Rp146B
CAGR 3-Years
19%
CAGR 5-Years
8%
CAGR 10-Years
4%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Accrued Liabilities
Rp372.3B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
17%
Soho Global Health Tbk PT
IDX:SOHO
Accrued Liabilities
Rp174.4B
CAGR 3-Years
2%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Accrued Liabilities
Rp98.5B
CAGR 3-Years
101%
CAGR 5-Years
89%
CAGR 10-Years
48%
Kimia Farma Tbk PT
IDX:KAEF
Accrued Liabilities
Rp513.5B
CAGR 3-Years
59%
CAGR 5-Years
28%
CAGR 10-Years
24%
No Stocks Found

Kalbe Farma Tbk PT
Glance View

Market Cap
64.6T IDR
Industry
Pharmaceuticals

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
1 429.6 IDR
Undervaluation 2%
Intrinsic Value
Price

See Also

What is Kalbe Farma Tbk PT's Accrued Liabilities?
Accrued Liabilities
782.7B IDR

Based on the financial report for Sep 30, 2024, Kalbe Farma Tbk PT's Accrued Liabilities amounts to 782.7B IDR.

What is Kalbe Farma Tbk PT's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
8%

Over the last year, the Accrued Liabilities growth was 13%. The average annual Accrued Liabilities growth rates for Kalbe Farma Tbk PT have been 2% over the past three years , 9% over the past five years , and 8% over the past ten years .

Back to Top